AviadoBio Announces FDA IND Clearance and Fast Track Designation for AVB-101 for the Treatment of Frontotemporal Dementia with Progranulin (GRN) Mutations

Contributed by: Business Wire

Logo

Business Wire logo

Tags

Biotechnology
Pharmaceutical
Oncology
General Health
Health
FDA
Genetics
Clinical Trials
FDA Clearance of IND Application